Newman Ferrara LLP Announces Corporate Governance Investigation of Ultragenyx Pharmaceutical Inc. - RARE
January 08 2018 - 2:07PM
Business Wire
Newman Ferrara LLP announced today that the firm is conducting
an investigation on behalf of shareholders of Ultragenyx
Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ:RARE)
into potential breaches of fiduciary duty by the Company’s Board of
Directors (the “Board”).
Ultragenyx, headquartered in Novato, CA, is a clinical-stage,
biopharmaceutical company focused on the treatment of genetic
diseases. Newman Ferrara’s investigation focuses on decisions made
by the Board, without shareholder approval, the result of which
significantly diminish shareholder value and do not benefit the
Company. Considering the Company’s lackluster performance since its
2014 initial public offering, it is clear that the Board lacks the
ability to fairly assess and oversee the Company’s direction and
leadership.
Current Ultragenyx stockholders seeking more information on this
matter are invited to contact Newman Ferrara attorneys Jeffrey
Norton (jnorton@nfllp.com) or Ryan Jerome (rjerome@nfllp.com) to
discuss this investigation and their rights.
Newman Ferrara maintains a multifaceted practice based in New
York City with attorneys specializing in complex commercial and
multi-party litigation, securities fraud and shareholder
litigation, consumer protection, civil rights, and real estate. For
more information, please visit the firm website at
www.nfllp.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180108006697/en/
Newman Ferrara LLPJeffrey M. Norton,
212-619-5400jnorton@nfllp.com
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From Apr 2023 to Apr 2024